JOURNAL SENTINEL; INCBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL SENTINEL; INC
Company Title:
Company Description:
Keywords to Search:
Company Address:	N1545 Powers Lake - Rd,WAUKESHA,WI,USA
ZIP Code: Postal Code:	53203
Telephone Number:	4144813029 (+1-414-481-3029)
Fax Number:	4144813195 (+1-414-481-3195)
Website:	awolacting. com
Email:
USA SIC Code(Standard Industrial Classification Code):	731304
USA SIC Description:	Media Brokers
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
CHOICE SOLUTIONS LLC
DIESEL & GAS TURBINE PUBLICAT
INTERNATIONAL ASSOCIATION OF MACHINISTS AND AEROSP

Next company profile:
AMERICAN TV APPLIANCE & FURN
PROMOGEN INC.
MC COY & HOFBAUER

Company News:

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Tirzepatide and semaglutide are highly effective medications for obesity management The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di
New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Recently Published | The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Original Article - The New England Journal of Medicine
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer
First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung . . .
Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3
Editorial - The New England Journal of Medicine
Musunuru and colleagues 1 describe in the Journal an innovative approach in which gene editing is applied in the treatment of a very rare disease, the severe urea-cycle disorder carbamoyl